AltaRex Licenses U.S. Issued Patents

AltaRex Corp. has obtained an exclusive worldwide license for a family of four U.S issued patents and foreign counterparts from the Alberta Research Council, Inc. (ARC) in Edmonton, Alberta.

These additions to the Company’s intellectual property portfolio provide AltaRex with a strong foundation for developing novel treatments in the area of autoimmune/inflammatory disease, such as multiple sclerosis, Crohn’s disease, and allergy/asthma.

The Company’s current proprietary technology applies to a number of disease areas (cancer, infectious disease and autoimmune/inflammatory disease), with current clinical development focused on cancer.

“We believe that we have a broad technology platform, and anticipate generating near term return from our antibodies to treat cancer.

We are prudently extending our intellectual property now, with a future focus on promising and synergistic therapeutic areas,” commented Richard E. Bagley, President and CEO of AltaRex Corp.

The family of U.S. issued patents obtained by AltaRex from the ARC includes three method patents titled ‘Anti Inflammatory Tolerogenic and Immunoinhibiting Properties of Carbohydrate Binding Peptides’ and one composition patent titled ‘Lectin Derived Carbohydrate Binding Peptides’. These patents are relevant to the Company’s established proprietary expertise in the use of binding agents, specifically antibodies, to alter patients’ immune system responses in a therapeutically beneficial manner.

The Alberta Research Council develops and commercialises technologies to give customers a competitive advantage.

The corporation performs applied research and development on a contract or fee basis, and co-ventures with others to develop new technologies, deriving a return on investment from the commercialisation of new products and processes.

ARC also conducts applied research projects for the public good and to support provincial science and technology needs and strategies.

AltaRex Corp. is primarily focused on the research, development and commercialisation of antigen-targeted antibody-based cancer therapies, utilizing monoclonal antibodies as immunotherapeutic agents for the treatment of certain late-stage cancers.

Purchase Dragon Pharma LLC On-line

Trenbolone 200 - Cheap Price

Administration: Injection
Active Constituent: Trenbolone Enanthate
Made by: Dragon Pharma Labs
Amount: 20 x 10 mL vial (200 mg/mL)
Price: 20 x $67.00

Masteron 100 - Cheap Price

Administration: Injection
Main Chemical Name: Drostanolone Di-Propionate
Manufacturer: Dragon Pharmaceutical
Package: 20 x 10 mL vial (100 mg/mL)
Price: 20 x $42.00

Trenbolone 200 - Discount Price

Administration: Injection
Prime Constituent: Trenbolone Enanthate
Branded by: Dragon Pharma
Unit: 30 x 10 mL vial (200 mg/mL)
Price: 30 x $57.00

Clomid - Bulk Price

Administration: Oral
Prime Chemical Name: Clomiphene Citrate
Produced by: Dragon Pharmaceutical
Amount: 10 x 100 pastilles (50 mg/tablet)
Price: 10 x $63.00

Primobolan 100

Injectable Anabolic Steroid
Primary Ingredient: Methenolone Enanthate
Producer: Dragon Pharmaceutical
Pack: 1 X 10 ml (100 mg/ml)

Clenbuterol - Discount Price

Administration: Oral
Primary Ingredient: Clenbuterol Hydrochloride
Branded by: Dragon Pharma Labs
Amount: 30 x 100 tabs (40 mcg/tablet)
Price: 30 x $20

NPP 150

Injectable Steroid for Muscle Growth
Principal Component: Nandrolone Phenylpropionate
Made by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (150 mg/mL)

Suspension 100

Injectable Steroid for Muscle Growth
Primary Constituent: Testosterone Suspension
Produced by: Dragon Pharma
10 mL Sterile Multi-dose Vial (100 mg/mL)


Oral Steroid for Muscle Growth
Basal Constituent: Chlorodehydromethyltestosterone
Produced by: Dragon Pharma
100 pills (20 mg/pill)

Masteron 200

Principal Ingredient: Drostanolone Enanthate
Made by: Dragon Pharma
Package: 10 mL vial (200 mg/mL)

TriTren 150

Basal Substance: Tri Trenbolone
Manufacturer: Dragon Pharma Labs
Pack: 10 mL vial (150 mg/mL)

Primobolan 200

Basal Component: Methenolone Enanthate
Made by: Dragon Pharma LLC
Amount: 10 mL vial (200 mg/mL)